Abstract | BACKGROUND: METHODS: Male ICR mice received CdCl2 (100 mg/l) via drinking water for 8 weeks. THU was administered intragastrically at dose of 50 or 100 mg/kg/day concurrently with Cd treatment. RESULTS: Administration of CdCl2 significantly increased arterial blood pressure, blunted vascular responses to vasoactive agents, increased aortic stiffness, and induced hypertrophic aortic wall remodeling by increasing number of smooth muscle cells and collagen deposition, decreasing elastin, and increasing matrix metalloproteinase (MMP)-2 and MMP-9 levels in the aortic medial wall. Supplementation with THU significantly decreased blood pressure, improved vascular responsiveness, and reversed the structural and mechanical alterations of the aortas, including collagen and elastin deposition. The reduction on the adverse response of Cd treatment was associated with upregulated eNOS and downregulated iNOS protein expressions, increased nitrate/ nitrite level, alleviated oxidative stress and enhanced antioxidant glutathione. Moreover, THU also reduced the accumulation of Cd in the blood and tissues. CONCLUSIONS: Our results suggest that THU ameliorates cadmium-induced hypertension, vascular dysfunction, and arterial stiffness in mice through enhancing NO bioavailability, attenuating oxidative stress, improving vascular remodeling and decreasing Cd accumulation in other tissues. THU has a beneficial effect in moderating the vascular alterations associated with Cd exposure.
|
Authors | Weerapon Sangartit, Upa Kukongviriyapan, Wanida Donpunha, Poungrat Pakdeechote, Veerapol Kukongviriyapan, Praphassorn Surawattanawan, Stephen E Greenwald |
Journal | PloS one
(PLoS One)
Vol. 9
Issue 12
Pg. e114908
( 2014)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25502771
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Protective Agents
- Cadmium
- tetrahydrocurcumin
- Nitric Oxide Synthase Type II
- Nitric Oxide Synthase Type III
- Nos2 protein, mouse
- Nos3 protein, mouse
- Curcumin
|
Topics |
- Animals
- Cadmium
(toxicity)
- Curcumin
(administration & dosage, analogs & derivatives)
- Gene Expression Regulation
(drug effects)
- Humans
- Hypertension
(chemically induced, drug therapy)
- Mice
- Nitric Oxide Synthase Type II
(biosynthesis)
- Nitric Oxide Synthase Type III
(biosynthesis)
- Oxidative Stress
(drug effects)
- Protective Agents
(administration & dosage)
- Vascular Remodeling
(drug effects)
- Vascular Stiffness
(drug effects)
|